趋化因子CCL2与肺癌的因果关系：两样本孟德尔随机化研究

doi:10.3969/j.issn.1006-5725.2024.04.016

Abstract

Abstract:

Objective To investigate whether chemokine CCL2 （also known as monocyte chemotactic protein 1 or MCP?1） has a causal relationship with lung cancer. Methods Genetic data of chemokine CCL2 and different pathological subtypes of lung cancer were extracted from genome?wide association studies （GWAS）， and inverse?variance weighted （IVW） analysis was used as main analysis， while weighted median， simple model， MR?Egger regression， and weighted model were chosen as supplementary analyses. Sensitivity analyses were performed to verify the reliability of the data. Results The result of IVW analysis on chemokine CCL2 to lung adenocarcinoma was OR = 1.065， 95%CI （0.919 ~ 1.234）， P = 0.401. The result of IVW analysis on chemokine CCL2 to squamous cell lung carcinoma was OR = 1.059， 95%CI （0.931 ~ 1.205）， P = 0.381. The result of IVW analysis on chemokine CCL2 to small cell lung carcinoma was OR = 0.959， 95%CI （0.760 ~ 1.208）， P = 0.720. Conclusions There is no direct causal relationship between chemokine CCL2 and lung cancer.

Key words: Mendelian randomization, monocyte chemokine, lung cancer, causality

CLC Number:

R734.2

Zishen LIU,Yingying ZHENG,Mengqi YUAN,Ganlin ZHANG,Guowang. YANG. The causal relationship between chemokine CCL2 and lung cancer： a two⁃sample Mendelian randomization study[J]. The Journal of Practical Medicine, 2024, 40(4): 532-536.

Figures/Tables 4

References 40

1	SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021， 71（3）： 209-249. doi:10.3322/caac.21660 doi: 10.3322/caac.21660
2	CHEN T Y， FANG Y H， CHEN H L， et al. Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women［J］. Sci Rep， 2020， 10（1）： 6774. doi:10.1038/s41598-020-63656-7 doi: 10.1038/s41598-020-63656-7
3	HUANG Y， ZHU M， JI M， et al. Air Pollution， Genetic Factors， and the Risk of Lung Cancer： A Prospective Study in the UK Biobank［J］. Am J Respir Crit Care Med， 2021， 204（7）： 817-825. doi:10.1164/rccm.202011-4063oc doi: 10.1164/rccm.202011-4063oc
4	JOSEPH A M， ROTHMAN A J， ALMIRALL D， et al. Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE （Smoking Cessation within the Context of Lung Cancer Screening） Collaboration［J］. Am J Respir Crit Care Med， 2018， 197（2）： 172-182. doi:10.1164/rccm.201705-0909ci doi: 10.1164/rccm.201705-0909ci
5	WANG M， HERBST R S， BOSHOFF C. Toward personalized treatment approaches for non-small-cell lung cancer［J］. Nat Med， 2021， 27（8）： 1345-1356. doi:10.1038/s41591-021-01450-2 doi: 10.1038/s41591-021-01450-2
6	BHUSAL R P， FOSTER S R， STONE M J. Structural basis of chemokine and receptor interactions： Key regulators of leukocyte recruitment in inflammatory responses［J］. Protein Sci， 2020， 29（2）： 420-432. doi:10.1002/pro.3744 doi: 10.1002/pro.3744
7	吴文娜，陈晓红. MCP-1的表达与高血压病、动脉粥样硬化的关系［J］. 实用医学杂志， 2011， 27（15）： 2876-2878.
8	LI L， LIU Y， ZHAN Y， et al. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma［J］. Thoracic Cancer， 2018， 9（7）： 775-784. doi:10.1111/1759-7714.12643 doi: 10.1111/1759-7714.12643
9	BURGESS S， DAVEY SMITH G， DAVIES N M， et al. Guidelines for performing Mendelian randomization investigations： update for summer 2023［J］. Wellcome Open Res， 2019， 4： 186. doi:10.12688/wellcomeopenres.15555.1 doi: 10.12688/wellcomeopenres.15555.1
10	FOLKERSEN L， GUSTAFSSON S， WANG Q， et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30，931 individuals［J］. Nat Metab， 2020， 2（10）： 1135-1148. doi:10.1038/s42255-020-00287-2 doi: 10.1038/s42255-020-00287-2
11	MCKAY J D， HUNG R J， HAN Y， et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes［J］. Nat Genet， 2017， 49（7）： 1126-1132.
12	PALMER T M， LAWLOR D A， HARBORD R M， et al. Using multiple genetic variants as instrumental variables for modifiable risk factors［J］. Stat Methods Med Res， 2012， 21（3）： 223-242. doi:10.1177/0962280210394459 doi: 10.1177/0962280210394459
13	XU M， WANG Y， XIA R， et al. Role of the CCL2-CCR2 signalling axis in cancer： Mechanisms and therapeutic targeting［J］. Cell Prolif， 2021， 54（10）： e13115. doi:10.1111/cpr.13115 doi: 10.1111/cpr.13115
14	FRANÇA C N， IZAR M C O， HORTÊNCIO M N S， et al. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease［J］. Clin Sci （Lond）， 2017， 131（12）： 1215-1224. doi:10.1042/cs20170009 doi: 10.1042/cs20170009
15	LIU H， YANG Z， LU W， et al. Chemokines and chemokine receptors： A new strategy for breast cancer therapy［J］. Cancer Med， 2020， 9（11）： 3786-3799. doi:10.1002/cam4.3014 doi: 10.1002/cam4.3014
16	MOADAB F， KHORRAMDELAZAD H， ABBASIFARD M. Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis： Latest evidence and therapeutic approaches［J］. Life Sci， 2021， 269： 119034. doi:10.1016/j.lfs.2021.119034 doi: 10.1016/j.lfs.2021.119034
17	YANG H， ZHANG Q， XU M， et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis［J］. Mol Cancer， 2020， 19（1）： 41. doi:10.1186/s12943-020-01165-x doi: 10.1186/s12943-020-01165-x
18	DING M， HE S J， YANG J. MCP-1/CCL2 Mediated by Autocrine Loop of PDGF-BB Promotes Invasion of Lung Cancer Cell by Recruitment of Macrophages Via CCL2-CCR2 Axis［J］. J Interferon Cytokine Res， 2019， 39（4）： 224-232. doi:10.1089/jir.2018.0113 doi: 10.1089/jir.2018.0113
19	CHEN C H， SU L J， TSAI H T， et al. ELF-1 expression in nasopharyngeal carcinoma facilitates proliferation and metastasis of cancer cells via modulation of CCL2/CCR2 signaling［J］. Cancer Manag Res， 2019， 11： 5243-5254. doi:10.2147/cmar.s196355 doi: 10.2147/cmar.s196355
20	FENG L， QI Q， WANG P， et al. Serum level of CCL2 predicts outcome of patients with pancreatic cancer［J］.Acta Gastroenterol Belg， 2020， 83（2）： 295-299.
21	XIE M， LIN Z， JI X， et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2［J］. J Hepatol， 2023， 79（1）： 109-125. doi:10.1016/j.jhep.2023.02.036 doi: 10.1016/j.jhep.2023.02.036
22	YOSHIMURA T， LI C， WANG Y， et al. The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis［J］. Cell Mol Immunol， 2023， 20（7）： 714-738. doi:10.1038/s41423-023-01013-0 doi: 10.1038/s41423-023-01013-0
23	WANG Y， ZHANG X， YANG L， et al. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer［J］. J Bone Oncol， 2018， 11： 27-32. doi:10.1016/j.jbo.2018.01.002 doi: 10.1016/j.jbo.2018.01.002
24	XU H， WANG J， AL-NUSAIF M， et al. CCL2 promotes metastasis and epithelial-mesenchymal transition of non-small cell lung cancer via PI3K/Akt/mTOR and autophagy pathways［J］. Cell Prolif， 2023： e13560. doi:10.1111/cpr.13560 doi: 10.1111/cpr.13560
25	YASUI H， KAJIYAMA H， TAMAUCHI S， et al. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway［J］. Clin Exp Metastasis， 2020， 37（1）： 145-158. doi:10.1007/s10585-019-09993-y doi: 10.1007/s10585-019-09993-y
26	WANG T， ZHAN Q， PENG X， et al. CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel［J］. Oncol Lett， 2018， 16（1）： 1267-1274.
27	KALBASI A， KOMAR C， TOOKER G M， et al. Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma［J］. Clin Cancer Res， 2017， 23（1）： 137-148. doi:10.1158/1078-0432.ccr-16-0870 doi: 10.1158/1078-0432.ccr-16-0870
28	SALCEDO R， PONCE M L， YOUNG H A， et al. Human endothelial cells express CCR2 and respond to MCP-1： direct role of MCP-1 in angiogenesis and tumor progression［J］. Blood， 2000， 96（1）： 34-40. doi:10.1182/blood.v96.1.34.013a49_34_40 doi: 10.1182/blood.v96.1.34.013a49_34_40
29	BONAPACE L， COISSIEUX M M， WYCKOFF J， et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis［J］. Nature， 2014， 515（7525）： 130-133. doi:10.1038/nature13862 doi: 10.1038/nature13862
30	WEI C， YANG C， WANG S， et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis［J］. Mol Cancer， 2019， 18（1）： 64. doi:10.1186/s12943-019-0976-4 doi: 10.1186/s12943-019-0976-4
31	CHEN X， YANG M， YIN J， et al. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling［J］. Cell Commun Signal， 2022， 20（1）： 92. doi:10.1186/s12964-022-00888-2 doi: 10.1186/s12964-022-00888-2
32	LI X， YAO W， YUAN Y， et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma［J］. Gut， 2017， 66（1）： 157-167. doi:10.1136/gutjnl-2015-310514 doi: 10.1136/gutjnl-2015-310514
33	MOISAN F， FRANCISCO E B， BROZOVIC A， et al. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers［J］. Mol Oncol 2014， 8（7）： 1231-1239. doi:10.1016/j.molonc.2014.03.016 doi: 10.1016/j.molonc.2014.03.016
34	QIAN B Z， LI J， ZHANG H， et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis［J］. Nature， 2011， 475（7355）： 222-225. doi:10.1038/nature10138 doi: 10.1038/nature10138
35	CHEN S， SHAO F， ZENG J， et al. Cullin-5 deficiency orchestrates the tumor microenvironment to promote mammary tumor development through CREB1-CCL2 signaling［J］. Sci Adv， 2023， 9（3）： eabq1395. doi:10.1126/sciadv.abq1395 doi: 10.1126/sciadv.abq1395
36	MA W J， LI Z H， WU Z R， et al. PI3K-CCL2-CCR2-MDSCs axis： A potential pathway for tumor Clostridia-promoted CD 8+ T lymphocyte infiltration in bile tract cancers［J］. Neoplasia 2023， 43： 100920. doi:10.1016/j.neo.2023.100920 doi: 10.1016/j.neo.2023.100920
37	HU W M， LI M， NING J Z， et al. FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression［J］. J Exp Clin Cancer Res， 2023， 42： 290. doi:10.1186/s13046-023-02860-5 doi: 10.1186/s13046-023-02860-5
38	ZHOU C， WENG J， LIU C， et al. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma［J］. Gastroenterology， 2023， 164（7）： 1261-1278. doi:10.1053/j.gastro.2023.02.005 doi: 10.1053/j.gastro.2023.02.005
39	KO K P， HUANG Y， ZHANG S， et al. Key Genetic Determinants Driving Esophageal Squamous Cell Carcinoma Initiation and Immune Evasion［J］. Gastroenterology， 2023， 165（3）： 613-628.e20. doi:10.1053/j.gastro.2023.05.030 doi: 10.1053/j.gastro.2023.05.030
40	PAN B， WAN T， ZHOU Y， et al. The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages［J］. Cancer Cell Int， 2023， 23（1）： 248. doi:10.1186/s12935-023-03079-2 doi: 10.1186/s12935-023-03079-2

GWAS ID	年份	名称	PMID	人群	样本量	Number of SNPs
ebi-a-GCST90012007	2020	单核细胞趋化蛋白1	33067605	European	21 758	13 137 212
ebi-a-GCST004744	2017	肺腺癌	28604730	European	66 756	7 849 324
ebi-a-GCST004750	2017	肺鳞癌	28604730	European	63 053	7 838 805
ebi-a-GCST004746	2017	小细胞肺癌	28604730	European	24 108	7 620 430

[1]	Yin HUA,Xiaoyan WANG,Zhen WANG,Yongning XIN,Shousheng. LIU. The relationship between ulcerative colitis and the risk of hypothyroidism： A two⁃mendelian randomization study [J]. The Journal of Practical Medicine, 2024, 40(6): 827-832.
[2]	Jiaming YANG,Shi XIE,Haishen ZHOU,Jiaqing ZHANG. A comparative study of clinical features and lymph node metastasis risk between early multi⁃primary and singlee pulmonary adenocarcinoma nodules [J]. The Journal of Practical Medicine, 2024, 40(22): 3208-3214.
[3]	Xinpan LI,Yi FANG,Jun QIU. Predictive value of CD3⁺/CD4⁺T lymphocyte level and neutrophil to lymphocyte ratio in radiation pneumonia [J]. The Journal of Practical Medicine, 2024, 40(20): 2923-2928.
[4]	Ling ZHU,Dewang REN,Runyang MA,Guowei LIANG,Xuejun. DOU. Methylation levels of the HIST1H4F gene mRNA region DNA and its diagnostic value in lung cancer tissues [J]. The Journal of Practical Medicine, 2024, 40(19): 2726-2732.
[5]	Xueyan HU,Fanliang MENG,Juanjuan. DONG. Prognostic analysis of patients with bone metastases from primary non-small cell lung cancer with different pathologic staging [J]. The Journal of Practical Medicine, 2024, 40(16): 2316-2325.
[6]	Shengfang YUAN,Bu WANG,Baoli XIANG,Jianqing ZHAO,Jingjing SHEN,Zhihua. ZHANG. Prediction of immune therapy efficacy and prognosis for advanced non-small cell lung cancer using peripheral blood circulation tumor DNA [J]. The Journal of Practical Medicine, 2024, 40(15): 2110-2115.
[7]	Lanrong WANG,Xiaocui WANG,Yang CAO,Rui LI,Weihong WANG,Yingxi XU,Weixiang SHI,Yufei YANG,Ke MENG,Wei. ZHANG. A cross⁃sectional study on the risk of early screening for lung cancer in Zhengzhou City [J]. The Journal of Practical Medicine, 2024, 40(15): 2154-2160.
[8]	Yuting LI,Qilu YAN,Qibin. SONG. Molecular basis of variability in EGFR⁃targeted therapy response in non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(15): 2166-2171.
[9]	Sijie ZHENG,Jia XIANG,Qiantong CHEN,Yingxin LU,Yun LIU,Huai CHEN,Suidan. HUANG. Differential diagnostic value of wide⁃body spectral CT parameters in mediastinal metastatic， non⁃metastatic lymph nodes of lung cancer patients and reactive hyperplastic lymph nodes [J]. The Journal of Practical Medicine, 2024, 40(14): 2003-2008.
[10]	Wendi ZHOU,Jiamin LIN,Daichen JU,Qi WANG,Jialou ZHU,Ning SU,Jinxing. HU. Proteomic profiling and functional analysis of differentially expressed proteins in lung cancer coexistent with pulmonary tuberculosis [J]. The Journal of Practical Medicine, 2024, 40(13): 1814-1821.
[11]	Xue MA,Shihui. ZHOU. Role and potential mechanisms of p62/SQSTM1 on migration and metastasis of non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2024, 40(1): 13-18.
[12]	Yang WU,Jian YAO,Jinliang. CHEN. The mechanism of lipid metabolism disorders promoting progression of lung cancer based on the oxLDL/LOX⁃1 signaling pathway [J]. The Journal of Practical Medicine, 2024, 40(1): 19-24.
[13]	Peng WANG,Sumei YAO,Xuedong LV,Jinliang. CHEN. Effect of the KLF14⁃mediated JAK⁃STAT signaling pathway on prognosis of lung cancer [J]. The Journal of Practical Medicine, 2024, 40(1): 25-31.
[14]	Ruiwen CHENG,Ruobing HAO,Ping LI,Kun ZHANG,Liping DENG,Yaheng CAO,Lin SU,Hongrong. SHEN. Clinical efficacy of CalliSpheres drug⁃loaded microspheres versus blank microspheres in the treatment of advanced non⁃small cell lung cancer by transarterial chemoembolization [J]. The Journal of Practical Medicine, 2024, 40(1): 32-37.
[15]	Yan WANG,Yajing HE,Lina HUANG,Yuwen. ZHANG. Analysis of common driver gene mutations in 661 cases of non⁃small cell lung cancer in eastern region of Henan Province [J]. The Journal of Practical Medicine, 2024, 40(1): 38-42.

The causal relationship between chemokine CCL2 and lung cancer： a two⁃sample Mendelian randomization study

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 40

Related Articles 15

Recommended Articles

Metrics

Comments